Psychiatric co-morbidity and substance use disorders: Treatment in parallel systems or in one integrated system

Substance Use and Misuse

Volumn 47, Issue 8-9, 2012, Pages 1005-1014

  Torrens, Marta ^a,b   Rossi, Paola C ^a   Martinez Riera, Roser ^a   Martinez Sanvisens, Diana ^a   Bulbena, Antoni ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

dual diagnosis; psychiatric co morbidity; services; substance use; treatment

Indexed keywords

ADDICTION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; COMORBIDITY; DEPRESSION; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MENTAL HEALTH SERVICE; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; REVIEW; TREATMENT OUTCOME;

ANXIETY DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMORBIDITY; DELIVERY OF HEALTH CARE, INTEGRATED; DEPRESSIVE DISORDER; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; MENTAL HEALTH SERVICES; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84862508123     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826084.2012.663296     Document Type: Article

References (90)

1. Abram, K. M., & Teplin, L. A. (1991). Co-occurring disorders among mentally ill jail detainees: Implications for public policy. American Psychologist, 46(10), 1036-1045.
2. Aharonovich, E., Liu, X., Nunes, E., & Hasin, D. S. (2002). Suicide attempts in substance abusers: Effects of major depression in relation to substance use disorders. American Journal of Psychiatry, 159(9), 1600-1602. (Pubitemid 35006746)
3. APA (American Psychiatric Association). (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th ed. Washington, DC: Author.
4. APA. (2004a). Practice guidelines for the treatment of patients with acute stress disorder and post-traumatic stress disorder. American Journal of Psychiatry, 160(11, Suppl.), 1-96.
5. APA. (2004b). Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry, 160(4, Suppl.), 1-184.
6. APA. (2007). Practice guideline for the treatment of patients with obsessive compulsive disorder. American Journal of Psychiatry, 164(7, Suppl.), 1-96.
7. APA. (2009). Practice guideline for the treatment of patients with panic disorder. American Journal of Psychiatry, 166(1, Suppl.), 1-90.
8. Appleby, L. (2000). Drugmisuse and suicide: A tale of two services. Addiction, 95(2), 175-177. (Pubitemid 30111229)
9. Barea, J., Benito, A., Mateu, C., Martin, E., Lopez, N., & Haro, G. (2010). Research on etiological aspects of dual pathology [Estudio sobre aspectos etiologicos de la patologia dual]. Adicciones, 22(1), 15-24.
10. Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2003). Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics, 111(1), 97-109. (Pubitemid 36071038)
11. Barkus, E., & Murray, R. M. (2010). Substance use in adolescence and psychosis: Clarifying the relationship. Annual Review of Clinical Psychology, 6, 365-389.
12. Barrowclough, C., Haddock, G., Tarrier, N., Lewis, S. W., Moring, J., O'Brien, R., et al. (2001). Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with co-morbid schizophrenia and substance use disorders. American Journal of Psychiatry, 158(10), 1706-1713. (Pubitemid 32923666)
13. Bellack, A. S., Bennett, M. E., Gearon, J. S., Brown, C. H., & Yang, Y. (2006). A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Archives of General Psychiatry, 63(4), 426-432.
14. Bowers, M. B., Jr, Mazure, C. M., Nelson, J. C., & Jatlow, P I (1990). Psychotogenic drug use and neuroleptic response. Schizophrenia Bulletin, 16(1), 81-85. (Pubitemid 20110377)
15. Brunette, M. F., Drake, R. E., Xie, H., McHugo, G. J., & Green, A I (2006). Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin, 32(4), 637-643. (Pubitemid 44412851)
16. Burnam, M. A., & Watkins, K. E. (2006). Substance abuse with mental disorders: Specialized public systems and integrated care. Health Affairs, 25(3), 648-658. (Pubitemid 43824914)
17. Canaway, R., &Merkes, M. (2010). Barriers to comorbidity service delivery: The complexities of dual diagnosis and the need to agree on terminology and conceptual frameworks. Australian Health Review, 34(3), 262-268.
18. Carey, M. P., Carey, K. B., Maisto, S. A., Gordon, C. M., & Vanable, P. A. (2001). Prevalence and correlates of sexual activity and HIV-related risk behavior among psychiatric outpatients. Journal of Consulting and Clinical Psychology, 69(5), 846-850. (Pubitemid 32973262)
19. Caton, C. L., Shrout, P. E., Eagle, P. F., Opler, L. A., Felix, A., & Dominguez, B. (1994). Risk factors for homelessness among schizophrenic men: A case-control study. American Journal of Public Health, 84(2), 265-270. (Pubitemid 24138463)
20. Clark, R. E., Samnaliev, M., & McGovern, M. P. (2009). Impact of substance disorders on medical expenditures for medicaid beneficiaries with behavioral health disorders. Psychiatric Services, 60(1), 35-42.
21. Cleary, M., Hunt, G. E., Matheson, S., & Walter, G. (2009). Psychosocial treatments for people with co-occurring severe mental illness and substance misuse: Systematic review. Journal of Advanced Nursing, 65(2), 238-258.
22. Compton, W. M., 3rd, Cottler, L. B., Jacobs, J. L., Ben-Abdallah, A., & Spitznagel, E. L. (2003). The role of psychiatric disorders in predicting drug dependence treatment outcomes. American Journal of Psychiatry, 160(5), 890-895. (Pubitemid 41079573)
23. Cuffel, B. J., Shumway, M., Chouljian, T. L., & MacDonald, T. (1994). A longitudinal study of substance use and community violence in schizophrenia. Journal of Nervous and Mental Disease, 182(12), 704-708.
24. Curran, G. M., Sullivan, G., Williams, K., Han, X., Collins, K., Keys, J., et al. (2003). Emergency department use of persons with comorbid psychiatric and substance abuse disorders. Annals of Emergency Medicine, 41(5), 659-667. (Pubitemid 36520245)
25. Davis, L., Uezato, A., Newell, J. M.,&Frazier, E. (2008).Major depression and comorbid substance use disorders. CurrentOpinion in Psychiatry, 21(1), 14-18. (Pubitemid 351339802)
26. Dickey, B., Azeni, H.,Weiss, R., & Sederer, L. (2000). Schizophrenia, substance use disorders and medical co-morbidity. Journal of Mental Health Policy and Economics, 3(1), 27-33.
27. Drake, R. E., Essock, S. M., Shaner, A., Carey, K. B., Minkoff, K., Kola, L., et al. (2001). Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services, 52(4), 469-476. (Pubitemid 32275306)
28. Drake, R. E., & Mueser, K. T. (2000). Psychosocial approaches to dual diagnosis. Schizophrenia Bulletin, 26(1), 105-118. (Pubitemid 30317695)
29. Drake, R. E., Mueser, K. T., & Brunette, M. F. (2007). Management of persons with co-occurring severe mental illness and substance use disorder: Program implications. World Psychiatry, 6(3), 131-136. (Pubitemid 350047816)
30. Drake, R. E., O'Neal, E. L., & Wallach, M. A. (2008). A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of Substance Abuse Treatment, 34(1), 123-138. (Pubitemid 350216356)
31. Drake, R. E.,Wallach,M. A.,&McGovern,M. P. (2005). Future directions in preventing relapse to substance abuse among clients with severe mental illnesses. Psychiatric Services, 56(10), 1297-1302. (Pubitemid 41407655)
32. Flynn, P. M.,& Brown, B. S. (2008). Co-occurring disorders in substance abuse treatment: Issues and prospects. Journal of Substance Abuse Treatment, 34(1), 36-47. (Pubitemid 350216354)
33. Frazer, A. (1997). Antidepressants. Journal of Clinical Psychiatry, 58(6 Suppl.), 9-25. (Pubitemid 27310165)
34. Gerra, G., Di Petta, G., D'Amore, A., Iannotta, P., Bardicchia, F., Falorni, F., et al. (2007). Combination of olanzapinewith opioidagonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clinical Neuropharmacology, 30(3), 127-135. (Pubitemid 46871862)
35. Grant, B. F., Hasin, D. S., Stinson, F. S., Dawson, D. A., Patricia Chou, S., June Ruan, W., et al. (2005). Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: Results from the national epidemiologic survey on alcohol and related conditions. Journal of Psychiatric Research, 39(1), 1-9. (Pubitemid 39422280)
36. Green, A I (2005). Schizophrenia and comorbid substance use disorder: Effects of antipsychotics. Journal of Clinical Psychiatry, 66 (6 Suppl.), 21-26. (Pubitemid 41243258)
37. Green, A. I., Canuso, C. M., Brenner, M. J., & Wojcik, J. D. (2003). Detection and management of comorbidity in patients with schizophrenia. Psychiatric Clinics of North America, 26(1), 115-139. (Pubitemid 36384351)
38. Green, A. I., Drake, R. E., Brunette, M. F.,&Noordsy, D. L. (2007). Schizophrenia and co-occurring substance use disorder. American Journal of Psychiatry, 164(3), 402-408. (Pubitemid 46513152)
39. Green, A. I., Noordsy, D. L., Brunette, M. F., & O'Keefe, C. (2008). Substance abuse and schizophrenia: Pharmacotherapeutic intervention. Journal of Substance Abuse Treatment, 34(1), 61-71. (Pubitemid 350216350)
40. Green, A. I., Salomon, M. S., Brenner, M. J., & Rawlins, K. (2002). Treatment of schizophrenia and comorbid substance use disorder. Current Drug Targets - CNS and Neurological Disorders, 1(2), 129-139.
41. Haddad, P. (1999). Do antidepressants have any potential to cause addiction? Journal of Psychopharmacology, 13(3), 300-307. (Pubitemid 29435798)
42. Haddock, G., Barrowclough, C., Tarrier,N., Moring, J.,O'Brien, R., Schofield, N., et al. (2003). Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. British Journal of Psychiatry, 183, 418-426. (Pubitemid 37357574)
43. Hasin, D., Nunes, E., & Meydan, J. (2004). Comorbidity of alcohol, drug and psychiatric disorders: Epidemiology. In H. R. Kranzler &I.A. Tinsley (Eds.), Dual diagnosis and psychiatric treatment: Substance abuse and comorbid disorders, 2nd ed. (pp. 1-31). New York: Marcel Dekker.
44. Hawkins, E. H. (2009). A tale of two systems: Co-occurring mental health and substance abuse disorders treatment for adolescents. Annual Review of Psychology, 60, 197-227.
45. Hill, A. B. (1965). The environment and disease: Associations or causation? Proceedings of the Royal Society of Medicine, 58, 295-300.
46. James, W., Preston, N. J., Koh, G., Spencer, C., Kisely, S. R., & Castle, D. J. (2004). A group intervention which assists patients with dual diagnosis reduce their drug use: A randomized controlled trial. Psychological Medicine, 34(6), 983-990. (Pubitemid 39199968)
47. Jasinski,D. R., Faries,D. E., Moore, R. J., Schuh, L. M.,&Allen, A. J. (2008). Abuse liability assessment of atomoxetine in a drugabusing population. Drug and Alcohol Dependence, 95(1-2), 140-146.
48. Kessler, R. C. (2004). The epidemiology of dual diagnosis. Biological Psychiatry, 56(10), 730-737. (Pubitemid 39539830)
49. Kessler, R. C., Nelson, C. B., McGonagle, K. A., Liu, J., Swartz, M., & Blazer, D. G. (1996). Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the US national comorbidity survey. British Journal of Psychiatry, (30 Suppl.), 17-30. (Pubitemid 26000488)
50. King, V. L., Kidorf, M. S., Stoller, K. B., & Brooner, R. K. (2000). Influence of psychiatric comorbidity on HIV risk behaviors: Changes during drug abuse treatment. Journal of Addictive Diseases, 19(4), 65-83.
51. Kollins, S. H. (2008). A qualitative review of issues arising in the use of psycho-stimulantmedications in patients with ADHD and co-morbid substance use disorders. Current Medical Research and Opinion, 24(5), 1345-1357. (Pubitemid 351741566)
52. Levin, F. R., Bisaga, A., Raby,W.,Aharonovich, E., Rubin, E.,Mariani, J., et al. (2008). Effects of major depressive disorder and attention-deficit/ hyperactivity disorder on the outcome of treatment for cocaine dependence. Journal of Substance Abuse Treatment, 34(1), 80-89. (Pubitemid 350216351)
53. Magura, S. (2000). Special issue on program quality in substance dependency treatment. Substance Use and Misuse, 34, 12-14.
54. Mariani, J. J., & Levin, F. R. (2007). Treatment strategies for co-occurring ADHD and substance use disorders. American Journal on Addictions, 16(1 Suppl.), 45-54; quiz 55-56.
55. Mart́in-Santos, R., Fonseca, F., Domingo-Salvany, A., Gińes, J.M., Imaz, M. L.,Navińes, R., et al. (2006).Dual diagnosis in the psychiatric emergency room in Spain. European Journal of Psychiatry, 20, 147-156 (Pubitemid 44974659)
56. McEvoy, J. P., Lieberman, J. A., Stroup, T. S.,Davis, S.M., Meltzer, H. Y., Rosenheck, R. A., et al. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry, 163(4), 600-610. (Pubitemid 44464569)
57. McKenzie,M. S.,&McFarland, B. H. (2007). Trends in antidepressant overdoses. Pharmacoepidemiology and Drug Safety, 16(5), 513-523. (Pubitemid 46824272)
58. McLellan, A. T., Luborsky, L., Woody, G. E., O'Brien, C. P., & Druley, K. A. (1983). Predicting response to alcohol and drug abuse treatments: Role of psychiatric severity. Archives of General Psychiatry, 40(6), 620-625. (Pubitemid 13094929)
59. Minkoff, K. (1991). Program components of a comprehensive integrated care system for serious mentally ill patients with substance disorders. New Directions for Mental Health Services, Summer(50), 13-27.
60. National Institute for Health and Clinical Excellence. (2009). Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). Retrieved July 7, 2009, from http://guidance.nice.org. uk/CG82/Guidance/pdf/English
61. Neale, J., Tompkins, C., & Sheard, L. (2008). Barriers to accessing generic health and social care services: A qualitative study of injecting drug users. Health & Social Care in the Community, 16(2), 147-154.
62. Noordsy, D. L., & Green, A I (2003). Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Current Psychiatry Reports, 5(5), 340-346. (Pubitemid 38899227)
63. Nunes, E. V., & Levin, F. R. (2004). Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. JAMA, 291(15), 1887-1896. (Pubitemid 38509503)
64. O'Brien, C. P. (2005). Benzodiazepine use, abuse, and dependence. Journal of Clinical Psychiatry, 66(2 Suppl.), 28-33.
65. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse: Results from the epidemiologic catchment area (ECA) study. JAMA, 264(19), 2511-2518.
66. Ridgely, M. S., Goldman, H. H., Willenbring, M. (1990). Barriers to the care of persons with dual diagnoses: Organizational and financing issues. Schizophrenia Bulletin, 16(1), 123-132. (Pubitemid 20110381)
67. Romach, M. K., & Doumani, S. (1998). Alcoholism and anxiety disorders. In H. R. Kranzler & B. J. Rounsaville (Eds.), Dual diagnosis and treatment: Substance abuse & comorbid medical & psychiatric disorders (Medical Psychiatry, Vol. 8) (pp. 137-176). New York: Marcel Dekker.
68. Rosenberg, S. D., Trumbetta, S. L., Mueser, K. T., Goodman, L. A., Osher, F. C., Vidaver, R. M., et al. (2001). Determinants of risk behavior for human immunodeficiency virus/acquired immunodeficiency syndrome in people with severe mental illness. Comprehensive Psychiatry, 42(4), 263-271. (Pubitemid 32656174)
69. Rounsaville, B. J., Kosten, T. R., Weissman, M. M., & Kleber, H. D. (1986). Prognostic significance of psychopathology in treated opiate addicts: A 2.5-year follow-up study. Archives of General Psychiatry, 43(8), 739-745. (Pubitemid 16035158)
70. Rounsaville, B. J., Tierney, T., Crits-Christoph, K., Weissman, M. M., & Kleber, H. D. (1982). Predictors of outcome in treatment of opiate addicts: Evidence for the multidimensional nature of addicts' problems. Comprehensive Psychiatry, 23(5), 462-478. (Pubitemid 13216263)
71. Sacks, S., Banks, S., McKendrick, K.,&Sacks, Y. (2008).Modified therapeutic community for co-occurring disorders: A summary of four studies. Journal of Substance Abuse Treatment, 34(1), 112-122. (Pubitemid 350218253)
72. Sacks, S., McKendrick, K., Sacks, J. Y., Banks, S., & Harle, M. (2008). Enhanced outpatient treatment for co-occurring disorders: Main outcomes. Journal of Substance Abuse Treatment, 34(1), 48-60. (Pubitemid 350216352)
73. Sacks, S., & Ries, R. K. (2005). TIP 42: Substance abuse treatment for persons with co-occurring disorders. Treatment Improvement Protocol (TIP) Series, 42. Rockville,MD: Substance Abuse and Mental Health Services Administration.
74. Sansone, R. A., & Sansone, L. A. (2010). Psychiatric disorders: A global look at facts and figures. Psychiatry, 7(12), 16-19.
75. Sayers, S. L., Campbell, E. C., Kondrich, J., Mann, S. C., Cornish, J., O'Brien, C., et al. (2005). Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. Journal of Nervous and Mental Disease, 193(6), 379-386. (Pubitemid 40800627)
76. Shanahan, M. D., Doran, C. M., Digiusto, E., Bell, J., Lintzeris, N., White, J., et al. (2006). A cost-effectiveness analysis of heroin detoxification methods in the Australian national evaluation of pharmacotherapies for opioid dependence (NEPOD). Addictive Behaviors, 31(3), 371-387. (Pubitemid 43288103)
77. Soyka, M. (2000). Substance misuse, psychiatric disorder and violent and disturbed behaviour. British Journal of Psychiatry, 176, 345-350.
78. Swartz,M. S., Swanson, J.W., Hiday, V. A., Borum, R.,Wagner, R., & Burns, B. J. (1998). Taking the wrong drugs: The role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. Social Psychiatry and Psychiatric Epidemiology, 33(1 Suppl.), S75-S80. (Pubitemid 28528991)
79. Thundiyil, J. G., Kearney, T. E., & Olson, K. R. (2007). Evolving epidemiology of drug-induced seizures reported to a poison control center system. Journal of Medical Toxicology, 3(1), 15-19.
80. Thylstrup, B., & Johansen, K. S. (2009). Dual diagnosis and psychosocial interventions: Introduction and commentary. Nordic Journal of Psychiatry, 63(3), 202-208.
81. Torrens,M., Fonseca, F.,Mateu, G., & Farre,M. (2005). Efficacy of antidepressants in substance use disorders with and without comorbid depression: A systematic reviewandmeta-analysis. Drug and Alcohol Dependence, 78(1), 1-22.
82. Torrens, M., Martin-Santos, R., & Samet, S. (2006). Importance of clinical diagnoses for comorbidity studies in substance use disorders. Neurotoxicity Research, 10(3-4), 253-261.
83. Torrens, M., Mart́inez-Sanvisens, D., Mart́inez-Riera, R., Bulbena, A., Szerman, N., & Ruiz, P. (2011). Dual diagnosis: Focusing on depression and recommendations for treatment. Addictive Disorders & Their Treatment, 10(2), 50-59.
84. Tsuang, J., Marder, S. R., Han, A., & Hsieh, W. (2002). Olanzapine treatment for patients with schizophrenia and cocaine abuse. Journal of Clinical Psychiatry, 63(12), 1180-1181. (Pubitemid 36084066)
85. Vazquez, C.,Munoz,M., & Sanz, J. (1997). Lifetime and 12-month prevalence of DSM-III-R mental disorders among the homeless in Madrid: A European study using the CIDI. Acta Psychiatrica Scandinavica, 95(6), 523-530. (Pubitemid 27272203)
86. Waid, L. R., Johnson, D. E., & Anton, R. F. (1998). Attentiondeficit hyperactivity disorder and substance abuse. In H. R. Kranzler & B. J. Rounsaville (Eds.), Dual diagnosis and treatment: Substance abuse & comorbid medical & psychiatric disorders (Medical Psychiatry,Vol. 8) (pp. 393-426).NewYork: Marcel Dekker.
87. Watkins, K. E., Hunter, S. B., Burnam, M. A., Pincus, H. A., & Nicholson, G. (2005). Review of treatment recommendations for persons with a co-occurring affective or anxiety and substance use disorder. Psychiatric Services, 56(8), 913-926. (Pubitemid 41098729)
88. Wilens, T. E., Adamson, J., Monuteaux, M. C., Faraone, S. V., Schillinger, M., Westerberg, D., et al. (2008). Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Archives of Pediatrics & Adolescent Medicine, 162(10), 916-921.
89. Wilens, T. E., & Biederman, J. (2006). Alcohol, drugs, and attention-deficit/hyperactivity disorder: A model for the study of addictions in youth. Journal of Psychopharmacology, 20(4), 580-588. (Pubitemid 43875189)
90. Wobrock, T., & Soyka, M. (2009). Pharmacotherapy of patients with schizophrenia and substance abuse. Expert Opinion on Pharmacotherapy, 10(3), 353-367.